Outcomes With Novel Therapies for Relapsed or Refractory Follicular Lymphoma: A Targeted Literature Review
Author(s)
Shah B1, Furnback W2, Xue M3, Esselman K2, Seymour EK3, Yang K3
1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA, 2Real Chemistry, New York, NY, USA, 3BeiGene USA, Inc, San Mateo, CA, USA
Presentation Documents
OBJECTIVES: Relapsed/refractory (R/R) follicular lymphoma (FL) treatments have evolved with the availability of novel agents. This targeted literature review (TLR) aimed to review outcomes associated with novel therapies in R/R FL.
METHODS: A TLR was conducted in Embase, PubMed, and conference databases to identify abstracts and manuscripts published from 1/1/2022-11/15/2023 that met inclusion criteria: (1) R/R FL; (2) ≥1 novel therapy, including chimeric antigen receptor T-cell therapy (CAR-T), enhancer of zeste homolog 2 (EZH2) inhibitors, bispecifics, or Bruton tyrosine kinase inhibitors (BTKis); and (3) clinical trials, real-world evidence (RWE) studies, comparative effectiveness research (CER), or pharmacoeconomic models. Non-English and phase 1b and earlier studies were excluded. Outcomes of interest were overall response rate (ORR), progression-free survival (PFS), overall survival, costs, and patient-reported outcomes (PROs).
RESULTS: Forty-three publications (12 trials, 8 CER, 2 RWE, and 3 models) were included. Three BTKis, 3 CAR-Ts, 3 bispecifics, 1 EZH2 inhibitor, and 1 antibody-drug conjugate (ADC) were identified. In 12 trials, ORRs were 86.2%-97% with CAR-Ts, 78.9%-97% with bispecifics, 36.4%-91.6% with BTKis, and 95.2% with ADC. Median PFS was 15.4-24 months with bispecifics, 5.8-40.5 months with BTKis, and 40.2 months in a CAR-T trial. PROs were reported in 3 trials. Improvements in fatigue, pain symptoms, and role function were greater with zanubrutinib + obinutuzumab than obinutuzumab monotherapy. CAR-Ts had improved efficacy vs controls and mosunetuzumab. A study of axicabtagene ciloleucel (axi-cel) vs tisagenlecleucel (tisa-cel) reported no difference in efficacy but an improved safety profile for tisa-cel. Tazemetostat demonstrated similar efficacy but an improved safety profile vs PI3Ks. In the third line, axi-cel was cost-effective vs standard of care, while another model favored mosunetuzumab over both axi-cel and tisa-cel.
CONCLUSIONS: Novel therapies have demonstrated promising efficacy results. Future research is needed to understand real-world long-term outcomes, impact on PROs, and treatment sequencing for R/R FL.
Conference/Value in Health Info
Value in Health, Volume 27, Issue 6, S1 (June 2024)
Code
SA7
Topic
Study Approaches
Topic Subcategory
Literature Review & Synthesis
Disease
Drugs, Oncology